<?xml version="1.0" encoding="UTF-8"?><faers xmlns="http://fda.gov/ns/faers"><meta><status>APPROVED</status><version>v2</version><patient-age>63</patient-age><report-id>PHHY2012PL113209</report-id><gender>male</gender><reactions><reaction>Itchy rash</reaction></reactions><drugs><drug><ndc>59572983</ndc><drug-name>NILOTINIB</drug-name><manufacturer/><ingredients/></drug></drugs><indications><indication>Chronic myeloid leukaemia</indication></indications><patient-age>63</patient-age><outcomes/><country>Poland</country><geo/></meta><original><ichicsr lang="en" xmlns="">
	<ichicsrmessageheader>
		<messagetype>ichicsr</messagetype>
		<messageformatversion>2.1</messageformatversion>
		<messageformatrelease>2.0</messageformatrelease>
		<messagenumb>4053102_286</messagenumb>
		<messagesenderidentifier>NovartisPH</messagesenderidentifier>
		<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
		<messagedateformat>204</messagedateformat>
		<messagedate>20121211133613</messagedate>
	</ichicsrmessageheader>
	<safetyreport>
		<safetyreportversion>1</safetyreportversion>
		<safetyreportid>PHHY2012PL113209</safetyreportid>
		<primarysourcecountry>PL</primarysourcecountry>
		<occurcountry>PL</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>2012-12-11</transmissiondate>
		<reporttype>1</reporttype>
		<serious code="2">No</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>2</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>2</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>2012-12-03</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>2012-12-03</receiptdate>
		<additionaldocument>2</additionaldocument>
		<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
		<companynumb>PHHY2012PL113209</companynumb>
		<medicallyconfirm>1</medicallyconfirm>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<reportercountry>PL</reportercountry>
			<qualification code="1">Physician</qualification>
		</primarysource>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<reportercountry>PL</reportercountry>
			<qualification code="5">Consumer or non-health professional</qualification>
		</primarysource>
		<sender>
			<sendertype>1</sendertype>
			<senderorganization>NOVARTIS PHARMACEUTICAL CORPORATION</senderorganization>
			<senderdepartment>Clinical Safety and Epidemiology</senderdepartment>
			<senderfamilyname>Clinical Safety and Epidemiology</senderfamilyname>
			<senderstreetaddress>Novartis Pharmaceuticals Corp. Bldg 419, One Health Plaza</senderstreetaddress>
			<sendercity>East Hanover</sendercity>
			<senderstate>NJ</senderstate>
			<senderpostcode>07936</senderpostcode>
			<sendercountrycode>US</sendercountrycode>
			<sendertel>+1800378</sendertel>
			<sendertelextension>8567</sendertelextension>
			<sendertelcountrycode>US</sendertelcountrycode>
			<senderfax>+1973781</senderfax>
			<senderfaxextension>8001</senderfaxextension>
			<senderfaxcountrycode>US</senderfaxcountrycode>
			<senderemailaddress>gdss.configuration@pharma.novartis.com</senderemailaddress>
		</sender>
		<receiver>
			<receivertype>2</receivertype>
			<receiverorganization>ZZFDA</receiverorganization>
			<receiverdepartment>FDA</receiverdepartment>
			<receivertitle>Mr</receivertitle>
			<receivergivename>William</receivergivename>
			<receiverfamilyname>Taylor</receiverfamilyname>
			<receiverstreetaddress>5600 Fishers Lane Room 16B-45</receiverstreetaddress>
			<receivercity>Rockville</receivercity>
			<receiverstate>MD</receiverstate>
			<receiverpostcode>20857</receiverpostcode>
			<receivercountrycode>US</receivercountrycode>
			<receivertel>+1301827</receivertel>
			<receivertelextension>0964</receivertelextension>
			<receivertelcountrycode>US</receivertelcountrycode>
			<receiverfax>+1301594</receiverfax>
			<receiverfaxextension>0829</receiverfaxextension>
			<receiverfaxcountrycode>US</receiverfaxcountrycode>
			<receiveremailaddress>.</receiveremailaddress>
		</receiver>
		<patient>
			<patientinitial>JD</patientinitial>
			<patientonsetage>63</patientonsetage>
			<patientonsetageunit>801</patientonsetageunit>
			<patientsex code="1">Male</patientsex>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Cholelithiasis</patientepisodename>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Cholangitis</patientepisodename>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Cholecystectomy</patientepisodename>
			</medicalhistoryepisode>
			<patientpastdrugtherapy>
				<patientdrugname>INTERFERON ALFA</patientdrugname>
				<patientdrgreactionmeddraversion>15.1</patientdrgreactionmeddraversion>
				<patientdrugreaction>10061822</patientdrugreaction>
			</patientpastdrugtherapy>
			<patientpastdrugtherapy>
				<patientdrugname>IMATINIB</patientdrugname>
				<patientdrugstartdateformat>102</patientdrugstartdateformat>
				<patientdrugstartdate>20010615</patientdrugstartdate>
			</patientpastdrugtherapy>
			<reaction>
				<primarysourcereaction>Itchy rash</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Itchy rash</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Rash pruritic</reactionmeddrapt>
				<reactionoutcome code="2">recovering/resolved</reactionoutcome>
			</reaction>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>NILOTINIB</medicinalproduct>
				<obtaindrugcountry>PL</obtaindrugcountry>
				<drugauthorizationnumb>22-068</drugauthorizationnumb>
				<drugauthorizationcountry>PL</drugauthorizationcountry>
				<drugauthorizationholder>NOVARTIS SECTOR: PHARMA</drugauthorizationholder>
				<drugdosagetext>UNK</drugdosagetext>
				<drugdosageform normalized="capsule">Capsule</drugdosageform>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Chronic myeloid leukaemia</drugindication>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>2010-10-26</drugstartdate>
				<actiondrug code="5">Unknown</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>AMN107</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Rash pruritic</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Rash pruritic</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
			</drug>
			<summary>
				<narrativeincludeclinical>Case number PHHY2012PL113209, is an <Semaphore x="1938518" class="Disease or Finding" value="First-Degree Burn" score="1.00" ID="C76130">initial </Semaphore>spontaneous report from a <Semaphore x="2398439" class="Occupation" value="Physician" score="1.00" ID="C25741">physician </Semaphore>via marketing program <Semaphore x="1780469" class="Disease or Finding" value="Chronic Myelogenous Leukemia, BCR-ABL1 Positive" score="1.00" ID="C3174">CML </Semaphore>experts project (number of Program 7297) received on 03 Dec 2012: This report refers to a 63-year old male patient. The patient's medical history included <Semaphore x="2857468" class="MedDRA LLT" value="Cholelithiasis" score="1.00" ID="10008629">cholelithiasis </Semaphore>with recurrent <Semaphore x="1589804" class="AnatomicStructure" value="Bile Duct Tissue" score="1.00" ID="C43615"><Semaphore x="1589804" class="AnatomicStructure" value="Bile Duct Tissue" score="1.00" ID="C43615">bile duct </Semaphore><Semaphore x="2055572" class="Disease or Finding" value="Inflammation" score="1.00" ID="C3137">inflammations</Semaphore>, </Semaphore>post <Semaphore x="1772635" class="Procedure" value="Cholecystectomy" score="1.00" ID="C51676">cholecystectomy </Semaphore>and historical <Semaphore x="1670730" class="Procedure" value="CAM Pharmacological or Biological Treatment" score="1.00" ID="C15906">drugs </Semaphore>included <Semaphore x="735567" class="Medicine" value="Interferon-alpha" score="0.74" ID="270116">interferon alpha </Semaphore>which <Semaphore x="2009057" class="Procedure" value="Health Assessment Prior to Exposure" score="1.00" ID="C88067">was not tolerated well </Semaphore>and <Semaphore x="699336" class="Medicine" value="imatinib" score="0.49" ID="252378">imatinib </Semaphore>to which both molecular and cytogenic progression had occurred. The patient's was <Semaphore x="1846062" class="Procedure" value="Diagnosis" score="1.00" ID="C15220">diagnosed </Semaphore>with <Semaphore x="1779493" class="Disease or Finding" value="Chronic Leukemia" score="1.00" ID="C3483">chronic <Semaphore x="3120003" class="MedDRA LLT" value="Myeloid leukaemia" score="1.00" ID="10028549">myeloid leukemia </Semaphore></Semaphore>in 1998. The patient received <Semaphore x="928154" class="Medicine" value="nilotinib" score="0.74" ID="278855">nilotinib </Semaphore>for the <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">treatment </Semaphore>of <Semaphore x="1779493" class="Disease or Finding" value="Chronic Leukemia" score="1.00" ID="C3483">chronic <Semaphore x="3120003" class="MedDRA LLT" value="Myeloid leukaemia" score="1.00" ID="10028549">myeloid leukemia </Semaphore></Semaphore>from 26 Oct 2010 at an unknown dose. On an unknown date, about 3 months after starting the suspect <Semaphore x="1670730" class="Procedure" value="CAM Pharmacological or Biological Treatment" score="1.00" ID="C15906">drug</Semaphore>, the patient experienced <Semaphore x="3221010" class="MedDRA LLT" value="Rash pruritic" score="1.00" ID="10037884">itchy rash</Semaphore>. The event was treated with <Semaphore x="798398" class="Medicine" value="Loratadine" score="0.49" ID="243030">loratadine </Semaphore>which <Semaphore x="1910095" class="Disease or Finding" value="Experimental Result" score="1.00" ID="C76125">resulted </Semaphore>in some improvement. The event was reported as related to <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">treatment </Semaphore>with <Semaphore x="928154" class="Medicine" value="nilotinib" score="0.74" ID="278855">nilotinib</Semaphore>. This case <Semaphore x="2123570" class="Disease or Finding" value="Lost To Follow-up" score="1.00" ID="C48227">lost to follow up</Semaphore>.</narrativeincludeclinical>
			</summary>
		</patient>
	</safetyreport>
</ichicsr></original></faers>